Table_1_Prognostic Roles of Blood Inflammatory Markers in Hepatocellular Carcinoma Patients Taking Sorafenib. A Systematic Review and Meta-Analysis.DOCX
Objective: The purpose of this meta-analysis is to investigate the effectiveness of the prognostic roles of blood inflammatory markers in hepatocellular carcinoma (HCC) patients receiving sorafenib.
Methods: We carried out a comprehensive literature search in four databases. Study endpoints, hazard ratios (HRs) and the associated 95% confidence intervals (CI) for clinical outcomes, which were to assess therapeutic efficacy, were extracted. This meta-analysis was conducted by Review Manager 5.3.
Results: We summarized the available evidence from 18 studies with a total of 2,745 cases. The pooled results showed that the synthesized HR favored patients with low pretreatment NLR (neutrophil-to-lymphocyte ratio), which also indicated that HCC patients with a lower baseline NLR may have a better response to sorafenib than those with higher NLR (HR = 1.76, 95% CI [1.44, 2.15], P < 0.00001, I2 = 68%). Significance was also observed for the prognostic function of the PLR (platelet-to-lymphocyte ratio) of HCC patients treated with sorafenib (HR = 1.49, 95% CI [1.16, 1.93], P = 0.002, I2 = 0%, P = 0.65). The subgroup analysis revealed that different gene backgrounds play a prominent role in the source of heterogeneity. Interestingly, the predictive effect on OS (overall survival) was more pronounced as the NLR cutoff value increased. Notably, a significant predictive effect of NLR on the clinical outcome was detected in HCC patients treated with sorafenib compared to those treated with tivantinib.
Conclusion: In conclusion, the present study reported promising predictive biomarkers for HCC patients and notably indicated that HCC patients with a lower baseline NLR and PLR may have a better response to sorafenib than those with higher ones. Further large-scale prospective studies are required to determine the optimal NLR and PLR cutoff values, which are important for identifying the dominant populations for sorafenib treatment.
History
References
- https://doi.org//10.3322/caac.21492
- https://doi.org//10.1016/S0140-6736(17)33326-3
- https://doi.org//10.1038/s41590-019-0429-7
- https://doi.org//10.1038/bjc.2014.46
- https://doi.org//10.1111/ctr.13151
- https://doi.org//10.3748/wjg.v24.i15.1658
- https://doi.org//10.1038/srep35378
- https://doi.org//10.14715/cmb/2017.63.8.7
- https://doi.org//10.1159/000485396
- https://doi.org//10.18632/oncotarget.9942
- https://doi.org//10.2307/2346307
- https://doi.org//10.7326/0003-4819-144-6-200603210-00010
- https://doi.org//10.1007/s10654-010-9491-z
- https://doi.org//10.18632/oncotarget.24769
- https://doi.org//10.1016/j.jhep.2017.06.026
- https://doi.org//10.18632/oncotarget.11565
- https://doi.org//10.1007/s12094-017-1720-4
- https://doi.org//10.1007/s12032-014-0264-5
- https://doi.org//10.18632/oncotarget.15322
- https://doi.org//10.18632/oncotarget.21528
- https://doi.org//10.18632/oncotarget.14797
- https://doi.org//10.1007/s12032-014-0969-5
- https://doi.org//10.3892/mco.2017.1416
- https://doi.org//10.1007/s12032-015-0549-3
- https://doi.org//10.7314/APJCP.2013.14.9.5527
- https://doi.org//10.2147/OTT.S173275
- https://doi.org//10.1111/j.1440-1746.2011.06887.x
- https://doi.org//10.1159/000493853
- https://doi.org//10.1158/1078-0432.CCR-18-0847
- https://doi.org//10.1016/j.cyto.2017.02.020
- https://doi.org//10.18632/oncotarget.21401
- https://doi.org//10.2217/bmm-2017-0307
- https://doi.org//10.1016/j.ijsu.2018.05.022
- https://doi.org//10.1155/2018/5670949
- https://doi.org//10.1158/1541-7786.MCR-05-0261
- https://doi.org//10.1038/nri3024
- https://doi.org//10.1038/nature07205
- https://doi.org//10.1007/978-3-0348-0837-8_16
- https://doi.org//10.1111/febs.14395
- https://doi.org//10.1038/nature23642
- https://doi.org//10.1038/nature11535
- https://doi.org//10.1016/j.cell.2011.10.043
- https://doi.org//10.1016/j.imbio.2017.07.001
- https://doi.org//10.1016/j.molimm.2017.10.009
- https://doi.org//10.1016/j.smim.2014.01.008
- https://doi.org//10.1007/s00280-013-2344-1
- https://doi.org//10.1007/s00262-012-1380-8
CC BY 4.0